This website might not be available on Saturday, 22 September 2019, between 08:00 IRST and 18:00 IRST, due to maintenance.
Submitted: 20 Feb 2017
Revised: 04 Apr 2017
Accepted: 07 Apr 2017
First published online: 17 May 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Cardiovasc Thorac Res. 2017;9(2):102-107.
doi: 10.15171/jcvtr.2017.17
PMID: 28740630
PMCID: PMC5516049
  Abstract View: 741
  PDF Download: 663

Original Article

Safety and effect of high dose allopurinol in patients with severe left ventricular systolic dysfunction

Mohammad Mostafa Ansari-Ramandi 1, Majid Maleki 1, Azin Alizadehasl 1, Ahmad Amin 1, Sepideh Taghavi 1, Mohammad Javad Alemzadeh-Ansari 1, Ali Kazem Moussavi 1, Nasim Naderi 1 *

1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Introduction: Allopurinol used in the treatment of gout has been shown to improve the vascular endothelial dysfunction and reduce the dysfunction of the failing heart. This study was done to evaluate the effect and safety of allopurinol in non-hyperuricemic patients with chronic severe left ventricular (LV) dysfunction.
Methods:
In this study, 35 consecutive cases of non-hyperuricemic patients with chronic heart failure who had severe LV systolic dysfunction (ejection fraction of less than 35%) and were on optimal guideline directed medical therapies for at least 3 months were included. Allopurinol was administered with the dose of 300 mg po daily for 1 week and then it was up-titrated to a dose of 600 mg po daily for 3 months. Six minute walk test, strain imaging, laboratory testing were done for every patient at baseline and after 3 months treatment with allopurinol.
Results:
In this study 30 heart failure (HF) patients with a mean age of 49.3 ± 14.4 years old were evaluated. No adverse effects were reported except for one case of skin rash after 4 days treatment which was excluded from the study. Study showed significant improvement of six minute walk test of the patients from 384.5 ± 81.5 meters to 402.8 ± 89.6 meters and the global longitudinal peak strain (P < 0.001). There was also significant decrease in the level of erythrocyte sedimentation rate and N-terminal pro-brain natriuretic peptide (NT-proBNP) after 3 months.
Conclusion: Allopurinol could be of benefit in non-hyperuricemic patients with severe LV systolic dysfunction without significant adverse effects. Randomized clinical trials are needed in future to confirm the results.
First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 741

Your browser does not support the canvas element.


PDF Downloaded: 663

Your browser does not support the canvas element.